NYSE:NVONovo Nordisk A/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $60.00 +0.36 (+0.60 %) (As of 04/10/2020 04:52 AM ET) Add Compare Share Today's Range$59.54Now: $60.00▼$60.7350-Day Range$49.46MA: $58.45▼$64.7852-Week Range$46.47Now: $60.00▼$64.82Volume3.01 million shsAverage Volume2.03 million shsMarket Capitalization$142.08 billionP/E Ratio24.39Dividend Yield1.88%Beta0.47 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $214.82, Novo Nordisk A/S has a potential upside of 258.0% from its current price of $60.00.Amount of Analyst CoverageNovo Nordisk A/S has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesNovo Nordisk A/S has received 344 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovo Nordisk A/S has received 447 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovo Nordisk A/S has received 56.51% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote “Outperform” if you believe NVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 3.3 Dividend Strength Dividend LeadershipNovo Nordisk A/S is a leading dividend payer. It pays a dividend yield of 1.88%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthNovo Nordisk A/S has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 45.53 %. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 35.33 % next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by InstitutionsOnly 7.20% of the stock of Novo Nordisk A/S is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Novo Nordisk A/S are expected to grow by 14.03% in the coming year, from $2.78 to $3.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 24.39, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 24.39, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.71.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 16.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.2Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.88 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVO Previous Symbol CUSIPN/A CIK353278 Webhttp://www.novonordisk.com/ Phone45-4444-8888Debt Debt-to-Equity Ratio0.05 Current Ratio1.06 Quick Ratio0.76Price-To-Earnings Trailing P/E Ratio24.39 Forward P/E Ratio21.58 P/E Growth1.99 Sales & Book Value Annual Sales$18.30 billion Price / Sales7.77 Cash Flow$2.89 per share Price / Cash Flow20.73 Book Value$3.65 per share Price / Book16.44Profitability EPS (Most Recent Fiscal Year)$2.46 Net Income$5.84 billion Net Margins31.95% Return on Equity73.70% Return on Assets32.49%Miscellaneous Employees43,258 Outstanding Shares2,368,001,000Market Cap$142.08 billion Next Earnings Date5/1/2020 (Estimated) OptionableOptionable Receive NVO News and Ratings via Email Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter. NVO Rates by TradingView Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions How has Novo Nordisk A/S's stock been impacted by COVID-19 (Coronavirus)? Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVO stock has increased by 3.6% and is now trading at $60.00. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Novo Nordisk A/S? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novo Nordisk A/S. When is Novo Nordisk A/S's next earnings date? Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for Novo Nordisk A/S. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Wednesday, February, 5th. The company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. The business had revenue of $4.80 billion for the quarter, compared to the consensus estimate of $4.83 billion. Novo Nordisk A/S had a net margin of 31.95% and a return on equity of 73.70%. View Novo Nordisk A/S's earnings history. How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S? Novo Nordisk A/S declared a semi-annual dividend on Friday, February 7th. Shareholders of record on Monday, March 30th will be given a dividend of $0.7874 per share on Tuesday, April 7th. This represents a yield of 1.4%. The ex-dividend date of this dividend is Friday, March 27th. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.32. View Novo Nordisk A/S's dividend history. What guidance has Novo Nordisk A/S issued on next quarter's earnings? Novo Nordisk A/S issued an update on its FY 2020 IntraDay earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.852-19.401 billion, compared to the consensus revenue estimate of $18.74 billion. What price target have analysts set for NVO? 9 equities research analysts have issued 1 year price targets for Novo Nordisk A/S's stock. Their forecasts range from $51.85 to $400.00. On average, they expect Novo Nordisk A/S's stock price to reach $214.82 in the next twelve months. This suggests a possible upside of 258.0% from the stock's current price. View analysts' price targets for Novo Nordisk A/S. Has Novo Nordisk A/S been receiving favorable news coverage? News coverage about NVO stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutNovo Nordisk A/S. Are investors shorting Novo Nordisk A/S? Novo Nordisk A/S saw a increase in short interest in March. As of March 13th, there was short interest totaling 5,108,900 shares, an increase of 9.9% from the February 27th total of 4,650,000 shares. Based on an average trading volume of 1,500,000 shares, the days-to-cover ratio is presently 3.4 days. Currently, 0.4% of the company's stock are sold short. View Novo Nordisk A/S's Current Options Chain. Who are some of Novo Nordisk A/S's key competitors? Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), QUALCOMM (QCOM), Starbucks (SBUX), Alibaba Group (BABA) and Walt Disney (DIS). Who are Novo Nordisk A/S's key executives? Novo Nordisk A/S's management team includes the following people: Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs What is Novo Nordisk A/S's stock symbol? Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO." Who are Novo Nordisk A/S's major shareholders? Novo Nordisk A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Clifford Swan Investment Counsel LLC (0.01%), Birch Capital Management LLC (0.00%), Carolina Wealth Advisors LLC (0.00%), Confluence Investment Management LLC (0.00%), Gradient Investments LLC (0.00%) and Chemung Canal Trust Co. (0.00%). View institutional ownership trends for Novo Nordisk A/S. Which institutional investors are selling Novo Nordisk A/S stock? NVO stock was sold by a variety of institutional investors in the last quarter, including Gradient Investments LLC, Clifford Swan Investment Counsel LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, CLARET ASSET MANAGEMENT Corp, Chemung Canal Trust Co., Adviser Investments LLC, Pinnacle Bank, and Global Trust Asset Management LLC. View insider buying and selling activity for Novo Nordisk A/S. Which institutional investors are buying Novo Nordisk A/S stock? NVO stock was bought by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, FNY Investment Advisers LLC, and Carolina Wealth Advisors LLC. View insider buying and selling activity for Novo Nordisk A/S. How do I buy shares of Novo Nordisk A/S? Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Novo Nordisk A/S's stock price today? One share of NVO stock can currently be purchased for approximately $60.00. How big of a company is Novo Nordisk A/S? Novo Nordisk A/S has a market capitalization of $142.08 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,258 workers across the globe. View additional information about Novo Nordisk A/S. What is Novo Nordisk A/S's official website? The official website for Novo Nordisk A/S is http://www.novonordisk.com/. How can I contact Novo Nordisk A/S? Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Google Finance Portfolio Tips and Tricks
